Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Maximilian Weniger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5178-8358; OpenAlex author ID A5072132914. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 15

  1. The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Co-author DOI 10.1155/mi/2632235↗
  2. Prognostic value of tumor-infiltrating lymphocytes, tumor associated neutrophils and metabolic checkpoint molecules on survival of patients with metastatic pan… Co-author DOI 10.1016/j.sipas.2025.100320↗
  3. SPOCK2 gene expression is downregulated in pancreatic ductal adenocarcinoma cells and correlates with prognosis of patients with pancreatic cancer. Co-author DOI 10.1007/s00432-023-04845-5↗
  4. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  5. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  6. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.07.025↗
  7. Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression. Co-author DOI 10.1016/j.ejso.2020.02.016↗
  8. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic ca… Co-author DOI 10.1016/j.pan.2019.10.007↗
  9. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  10. The quality of pain management in pancreatic cancer: A prospective multi-center study. First author DOI 10.1016/j.pan.2020.08.017↗
  11. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  12. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Co-author DOI 10.1016/j.suronc.2019.08.010↗
  13. Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Co-author DOI 10.3390/cancers11010039↗
  14. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. First author DOI 10.1007/s11523-018-0578-x↗
  15. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship. Co-author DOI 10.3390/cancers10090316↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jan Goesta D’Haese · 10 shared papers, 2018–2026 · strength 1.41
  2. Jens Werner · 9 shared papers, 2018–2026 · strength 1.32
  3. Rainer Christoph Miksch · 4 shared papers, 2019–2026 · strength 0.76
  4. Matthias Ilmer · 4 shared papers, 2019–2026 · strength 0.72
  5. Alexandr V. Bazhin · 4 shared papers, 2018–2025 · strength 0.61
  6. Bernhard Willibald Renz · 3 shared papers, 2019–2026 · strength 0.61
  7. Motaz Qadan · 4 shared papers, 2020–2022 · strength 0.46
  8. Keith D. Lillemoe · 4 shared papers, 2020–2022 · strength 0.46
  9. Ughur Aghamaliyev · 2 shared papers, 2023–2025 · strength 0.43
  10. Guralp Onur Ceyhan · 4 shared papers, 2019–2020 · strength 0.36
  11. Carlos Fernández-del Castillo · 3 shared papers, 2021–2022 · strength 0.35
  12. Cristina Rosa Ferrone · 3 shared papers, 2020–2021 · strength 0.34
  13. Andrew Louis Warshaw · 3 shared papers, 2020–2022 · strength 0.34
  14. Thomas P. Hank · 3 shared papers, 2020–2022 · strength 0.34
  15. Steffen Ormanns · 2 shared papers, 2019–2025 · strength 0.33
  16. Patrick Maisonneuve · 3 shared papers, 2020 · strength 0.31
  17. Yang Feng Wu · 1 shared paper, 2026 · strength 0.29
  18. Qi Li · 1 shared paper, 2026 · strength 0.29
  19. Marko Damm · 3 shared papers, 2020 · strength 0.27
  20. John A. G. Moir · 3 shared papers, 2020 · strength 0.27
  21. Stephan Schorn · 3 shared papers, 2020 · strength 0.27
  22. Jonas Rosendahl · 3 shared papers, 2020 · strength 0.27
  23. Andrew Scott Liss · 2 shared papers, 2018–2021 · strength 0.25
  24. Tao Zhang · 1 shared paper, 2025 · strength 0.23
  25. Marta Sandini · 2 shared papers, 2020–2022 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.